Stay updated on Efficacy Safety in Primary IgA Nephropathy Clinical Trial

Sign up to get notified when there's something new on the Efficacy Safety in Primary IgA Nephropathy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efficacy Safety in Primary IgA Nephropathy Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T06:36:33.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new version of the study protocol for the Nef-301 OLE study, changing from a Phase 3b multicenter study description to an open-label, single-arm study format. Additionally, the name of the study director has been updated to Richard Philipson, MD.
    Difference
    24%
    Check dated 2025-04-16T21:43:16.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The web page has updated its date information, removing the date '2025-03-25' and adding new dates including '2025-02-10', '2024-12-16', and '2025-01-03'. Additionally, the revision number has changed from 'v2.14.3' to 'v2.14.4'.
    Difference
    0.8%
    Check dated 2025-04-09T16:53:59.000Z thumbnail image
  6. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    2%
    Check dated 2025-02-24T23:20:53.000Z thumbnail image
  7. Check
    80 days ago
    Change Detected
    Summary
    The page has updated its scoring dates, reflecting new health scores for 2025, while removing older dates from 2024.
    Difference
    0.9%
    Check dated 2025-02-17T19:43:54.000Z thumbnail image
  8. Check
    87 days ago
    Change Detected
    Summary
    The page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.
    Difference
    2%
    Check dated 2025-02-10T17:17:55.000Z thumbnail image

Stay in the know with updates to Efficacy Safety in Primary IgA Nephropathy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efficacy Safety in Primary IgA Nephropathy Clinical Trial page.